CVNA three-lens brief
Evidence-based stock research on CVNA. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Analyst mean target $92.14 — 35% above current (21 analysts).
- Earnings scheduled 2026-07-29.
CVNA closed at $68.04 (+1.37%) as of 2026-07-10. Market cap: $74.63B. P/E (trailing) 39.6. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $92.14 — 35% above current (21 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $6.43B, net income $405.00M, free cash flow $196.75M. Watching for: 2026-07-29 earnings release (18 days out).
Why three lenses on CVNA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CVNAacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CVNA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CVNA brief"></iframe>